This is the authors' abstract. We don't add key points for this paper.
427 Recently, we reported on the rational design of novel immunomodulatory peptides. Administration of these peptides into mice and rats resulted in the upregulation of hemoxygenase-1 (HO-1). Upregulation of HO-1 was associated with the inhibition of several immune effector functions including lymphocyte proliferation, INFγ and TNFα production. Analysis of peptide mediated inhibition of TNFα production by RT-PCR and immunoprecipitation demonstrated that the reduction of TNFα production was due to decreased translation but not gene transcription. TNFα is a proinflammatory agent and appears to be involved in the pathology of several diseases including graft versus host disease (GVHD). The effect of one of these peptides, Allotrap 1258 was tested in a scid-hu mouse model for human graft versus host disease (GVHD). Pretreatment of scid mice with anti-asialo GM-1 antiserum and radiation allowed the successful transplantation of human peripheral blood lymphocytes into these animals. All of the Hu-PBL-scid mice died of GVHD within 5 weeks post transplantation. To test the effect of Allotrap 1258 on GVHD, mice (n=25) were treated intraperitoneally with 1 mg/kg/day Allotrap 1258 three times per week for two weeks. Peptide therapy prolonged animal survival 2.6 times (MST= 66 vs 25 days, p=0.008). Human cytokine levels in serum were determined at 3 weeks post cell infusion. Compared to control animals human TNFα and IFNg concentrations were reduced by 57% (peptide treated 8.7±3.2 units/ml vs control 20.1±4.5 units/ml; p=.001) and 47% (peptide treated 6.8±2.3 units/ml vs control 12.9±2.6 units/ml; p=.002), respectively. The human immunoglobulin levels in experimental mice were reduced by 63% compared to control animals (peptide treated 531±436 mg/l vs control 1429±329 mg/l; p=.006). Statistical analysis were done using student's t test. These results demonstrate that Allotrap 1258 not only modulates immune responses of rodent but also human lymphocytes. Peptide therapy of scid-hu mice attenuated GVHD and prolonged animal survival suggesting that Allotrap 1258 may have potential for suppressing GVHD reactions in humans.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: